Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-75
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

About this trial

To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2\~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.

Eligibility criteria

Qualifiers

Clearly diagnosed with nasopharyngeal carcinoma by pathology;

Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;

Patients diagnosed in our hospital from January 2025 to December 2028;

Have relatively complete clinical data;

Disqualifiers

The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;

The participants failed to obtain pathological and imaging data for various reasons;

Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.

Trial design

Treatments tested in this trial

  • No Intervention

Treatment groups

600 Participants
are divided into 1 treatment group

Locations

This trial has no locations